Design Therapeutics Q2 net loss $11.8M; cash $261M; FA and FECD programs on track

Design Therapeutics, Inc.

2024-Q2 EPS reported -$0.41

Net loss $11.8M for Q2 2024; R&D expense $10.5M, G&A expense $4.5M.
Cash, cash equivalents and marketable securities $261.0M as of June 30; runway into 2029.
FA program DT-216P2 on track to start patient trials in 2025 after GLP studies complete.
FECD program DT-168 to begin Phase 1 in healthy volunteers in 2024; 200-patient observational study ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.